| Autor: |
Agallou M; Immunology of Infection Group, Department of Microbiology, Hellenic Pasteur Institute, 115 21 Athens, Greece., Margaroni M; Immunology of Infection Group, Department of Microbiology, Hellenic Pasteur Institute, 115 21 Athens, Greece., Karagouni E; Immunology of Infection Group, Department of Microbiology, Hellenic Pasteur Institute, 115 21 Athens, Greece. |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccines [Vaccines (Basel)] 2023 Aug 19; Vol. 11 (8). Date of Electronic Publication: 2023 Aug 19. |
| DOI: |
10.3390/vaccines11081384 |
| Abstrakt: |
Control of the intracellular parasite Leishmania ( L .) requires the activation of strong type 1 cellular immune responses. Towards this goal, in the present study, a multiepitope chimeric protein named LiChimera was encapsulated into cationic liposomes and its protective efficacy against experimental visceral leishmaniasis was investigated. Liposomal LiChimera conferred significant protection against L. infantum as evidenced by the significantly reduced parasite loads in the spleen and liver. Protection detected in Lipo:LiChimera-immunized mice was dependent on the differentiation of long-lasting cellular immune responses and particularly the induction of antigen-specific multifunctional memory CD4 + T H 1 and CD8 + T cells that persisted during infection, as evidenced by the persistent high production of IFN-γ and IL-2 and proliferation activity. Notably, protected mice were also characterized by significantly low numbers of non-regulatory CD4 + T cells able to co-produce IFN-γ and IL-10, an important population for disease establishment, as compared to non-immunized control group. Collectively, these results demonstrate that cationic liposomes containing LiChimera can be considered an effective candidate vaccine against visceral leishmaniasis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
